Chardan Capital Markets Downgrades Mesoblast Limited (MESO) to Neutral

Chardan Capital Markets downgraded Mesoblast Limited (NASDAQ: MESO) from to Neutral with a price target of $5.50.

Analyst Keay Nakae commented, "There are certainly a number of things to like about Mesoblast. The company's proprietary mesenchymal lineage adult stem cells (MLCs) can be formulated into allogenic "off-the-shelf" cell products, which it is capable of producing at commercial scale through its strategic alliance with Lonza, a global leader in biopharmaceutical manufacturing. As a result, Mesoblast possesses an advanced clinical pipeline with five cell therapy product candidates that are in active Phase 3 trials or are Phase 3-ready. Most of these indications represent large market opportunities, so success in any one of them could generate significant economics for the company."

For an analyst ratings summary and ratings history on Mesoblast Limited click here. For more ratings news on Mesoblast Limited click here.

Shares of Mesoblast Limited closed at $5.07 yesterday.

You May Also Be Interested In

• GLJ Research Downgrades Fluence Energy Inc. (FLNC) to Hold
• Bernstein on whether Hershey (HSY) could eventually step up to buy Mondelez (MDLZ)
• Deutsche Bank Starts Ardagh Metal Packaging S.A. (AMBP) at Hold